&NA;Fasidotril (BP 1137, alatriopril, aladotril), the prodrug of its active metabolite fasidoprilat, is a mixed inhibitor of ACE and neutral endopeptidase (NEP). It is currently undergoing phase II development with Bioprojet in France for the treatment of congestive heart failure (CHF) and appears to be undergoing clinical investigation for the treatment of hypertension.